
Impel Pharmaceuticals Investor Relations Material
Latest events

Q1 2023
Impel Pharmaceuticals

Q3 2023
14 Nov, 2023

Q2 2023
18 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Impel Pharmaceuticals Inc
Access all reports
Impel Pharmaceuticals Inc is a biopharmaceutical company that develops intranasal drug delivery treatments for central nervous system disorders. The company’s delivery platform enables rapid and targeted administration of therapeutics for conditions such as migraines and Parkinson’s disease. It focuses on commercializing treatments through healthcare provider networks. Impel Pharmaceuticals Inc is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
IMPL
Country
🇺🇸 United States